EndoLipiD Therapeutics

EndoLipiD Therapeutics is a private, preclinical-stage biotech leveraging a novel mechanism of action—mimicking the endogenous protein SHBG—to address diseases of ectopic fat accumulation. Its lead program, EDL6D, targets NASH with demonstrated efficacy in reducing liver fat, inflammation, and fibrosis in animal models, while a second program, EDL81 (Ac-EDL67), for cellulite is in co-development with Nanovex Biotechnologies. The company is supported by venture capital, public grants including EU Next Generation funds, and a crowdfunding campaign, and is led by a team combining deep scientific expertise in SHBG biology with clinical and business development experience.

Platform for designing synthetic peptides that mimic the function of Sex Hormone-Binding Globulin (SHBG) to reduce ectopic fat accumulation via a novel receptor-mediated mechanism affecting lipolysis, lipogenesis, inflammation, and fibrosis.

In NASH, EndoLipiD faces intense competition from large pharma and biotechs with advanced clinical assets, though its novel MoA provides differentiation. In cellulite, competition comes from aesthetic device companies and cosmetic creams, but few offer a peptide-based, biologically-targeted approach, potentially creating a unique niche.